Genitourinary Drugs Companies, Market Entry and Expansion Strategies

Genitourinary Drugs Market Companies with Market Growth 2026-2035

Genitourinary Drugs Market Companies with Latest Offerings

Abbott

Headquarters: Abbott Park, Illinois, USA
Offerings: Abbott specializes in diagnostic tests for bladder cancer and sexually transmitted infections (STIs). Additionally, the company emphasizes pharmaceuticals focused on women’s health.

Bristol-Myers Squibb Co.

Headquarters: New York, USA
Offerings: Bristol-Myers Squibb facilitates treatments for kidney, bladder, and prostate cancers.

Novartis AG

Headquarters: Basel, Switzerland
Offerings: Novartis primarily focuses on prostate cancer and rare kidney diseases. Its recently approved drugs include Pluvicto for prostate cancer, and Fabhalta and Vanrafia for kidney diseases.

Genentech, Inc.

Headquarters: South San Francisco, California, USA
Offerings: Genentech introduced Tecentriq (atezolizumab), an immunotherapy approved for specific types of bladder and urinary tract cancers.

Eli Lilly and Company

Headquarters: Indianapolis, Indiana, USA
Offerings: Eli Lilly offers Cialis (tadalafil) for erectile dysfunction and benign prostatic hyperplasia.

Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Offerings: Merck provides diverse genitourinary (GU) oncology drugs, including KEYTRUDA (pembrolizumab) and WELIREG (belzutifan).

Pfizer, Inc.

Headquarters: New York, USA
Offerings: Pfizer focuses on drugs used for treating prostate, bladder, and kidney cancers.

AstraZeneca

Headquarters: Cambridge, United Kingdom
Offerings: AstraZeneca has unveiled Imfinzi for bladder cancer and Lynparza for prostate cancer.

GlaxoSmithKline (GSK)

Headquarters: Brentford, United Kingdom
Offerings: GSK received approval for the oral antibiotic Blujepa (gepotidacin), used for uncomplicated urinary tract infections (uUTIs) and urogenital gonorrhea.

Bayer AG

Headquarters: Leverkusen, Germany
Offerings: Bayer explores drugs for prostate cancer and chronic kidney disease, including Nubeqa and Xofigo.

Genitourinary Drugs Market- Value Chain Analysis

R&D

• Through the various stages, such as discovery, preclinical & clinical study, and then post-marketing process, the market is focusing on new treatments for concerns affecting the urinary and reproductive systems.
• Key Players: Pfizer, Merck, Novartis, etc.

Clinical Trials & Regulatory Approvals

• Four main phases of trials are aiming to treat cancers by utilizing new immunotherapies, like nivolumab, pembrolizumab, and targeted agents, including cabozantinib and enfortumab vedotin, and finally receiving authorization from regulatory bodies, like the FDA & EMA.
• Key Players: Sarah Schlegel, Hospital Regional 1o de Octubre, Spanish Oncology Genito-Urinary Group, etc.

Patient Support & Services

• This mainly covers patient education, medication management, and specialized support programs led by healthcare providers, pharmacists, and pharmaceutical firms. 
• Key Players: ProPharma, HDU Healthcare, Merck, etc.

Market Growth

The global genitourinary drugs market size was estimated at USD 30.1 billion in 2025 and is predicted to increase from USD 30.45 billion in 2026 to approximately USD 33.75 billion by 2035, expanding at a CAGR of 1.15% from 2026 to 2035.

What are the Key Developments in the Genitourinary Drugs Market

• In August 2025, K36 Therapeutics, Inc., received the US FDA clearance of the Investigational New Drug (IND) Application for KTX-2001, a selective, oral inhibitor of NSD2 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
• In August 2025, Gedeon Richter UK introduced Nalvee (10mg dydrogesterone) in the UK, a hormone replacement therapy for non-hysterectomised women receiving oestrogen therapy.

Partner with our experts to explore the Genitourinary Drugs Market at sales@towardshealthcare.com